[CEPTOR CORPORATION LOGO OMITTED] Exhibit 99.1
FOR IMMEDIATE RELEASE
CONTACTS:
Donald C. Weinberger
Donald W. Fallon, CFO Alisa D. Steinberg (Media)
CEPTOR CORPORATION WOLFE AXELROD WEINBERGER ASSOC. LLC
(410) 527-9998 Fax (410) 527-9867 (212) 370-4500 Fax (212) 370-4505
dfallon@ceptorcorp.com don@wolfeaxelrod.com
alisa@wolfeaxelrod.com
CEPTOR REPORTS TWO ISSUES REMAIN TO MOVE MYODUR IND FORWARD
- FDA INSTRUCTS COMPANY TO ADDRESS TWO ISSUES BEFORE GRANTING CLEARANCE
TO BEGIN HUMAN MUSCULAR DYSTROPHY TRIALS -
HUNT VALLEY, MD - OCTOBER 6, 2006 -- CEPTOR CORPORATION (OTC BB: CEPO), a
biopharmaceutical company focusing on cell-targeted therapeutic products for
neuromuscular and neurodegenerative diseases, announced today that its
Investigational New Drug application (IND) for Myodur to be used in Duchenne
muscular dystrophy trials remains on hold. In a teleconference with the FDA, the
agency reported that there are two remaining issues that it would like the
Company to address before moving into human trials. The Company reported that
the remaining two items are straightforward and addressable.
-------------------------------
ABOUT CEPTOR CORPORATION
CepTor Corporation is a development-stage biopharmaceutical company engaged in
the discovery, development, and commercialization of proprietary, cell-targeted
therapeutic products for the treatment of neuromuscular and neurodegenerative
diseases with a focus on orphan diseases. CepTor's primary efforts are currently
focused on moving its lead product, Myodur, into clinical trials for Duchenne
muscular dystrophy. The Company's broad platform technology also includes the
development of products for multiple sclerosis (MS), chronic inflammatory
demyelinating polyneuropathy (CIDP) and amyotrophic lateral sclerosis (ALS).
More information about CepTor can be found at www.ceptorcorp.com.
The press release contains forward-looking statements. These statements are
subject to known and unknown risks and uncertainties that may cause actual
future experience and results to differ materially from the statements made.
These statements are based on our current beliefs and expectations as to such
future outcomes. Drug discovery and development involves a high degree of risk.
Factors that might cause such a material difference include, among others,
uncertainties related to the ability to attract and retain partners for our
technologies, the identification of lead compounds, the successful preclinical
development thereof, the completion of clinical trials, the FDA review process
and other government regulation on our ability to successfully develop and
commercialize drug candidates, competition from other pharmaceutical companies,
product pricing and third party reimbursement. The Company disclaims any
obligation to update any forward-looking statement as a result of developments
occurring after the date of this press release.
###
